Thomas E. Keane, MD, presented “Timing of ADT with Chemotherapy in 2019” during the 29th Annual International Prostate Cancer Update on January 26, 2019 in Beaver Creek, Colorado.
How to cite: Keane, Thomas E. “Timing of ADT with Chemotherapy in 2019” January 26, 2019. Accessed Oct 2019. https://grandroundsinurology.com/timing-of-adt-with-chemotherapy-in-2019/
Timing of ADT with Chemotherapy in 2019 – Summary:
Thomas E. Keane, MD, reviews the data supporting and opposing the advancement of chemotherapy into the metastatic castration-sensitive prostate cancer (mCSPC) disease state. He then discusses a current trial introducing chemotherapy in patients prior to androgen deprivation therapy (ADT).
The use of chemotherapy in prostate cancer has typically been reserved for patients with very advanced disease. Recently, as a result of a number of phase III randomized, controlled trials, this modality has been advanced to the castrate-sensitive metastatic disease state with very encouraging results.
The results of the E3805 (CHAARTED) trial were surprising to the urologic community. It showed a significant overall survival benefit with chemohormonal therapy in mCSPC patients. However, only patients with high-volume prostate cancer saw benefits in extent of metastatic disease. The STAMPEDE trial then confirmed the observations from CHAARTED.
On the contrary, the GETUG-AFU 15 study showed a highly significant biochemical progression-free survival, but no overall survival benefit to docetaxel plus androgen-deprivation therapy (ADT) in mCSPC. Notably, patients who failed in GETUG-AFU 15 did not have the availability of enzalutamide and abiraterone, while those in CHAARTED did.
When comparing toxicity data from GETUG-AFU 15, CHAARTED, and TAX327, the study that led to docetaxel’s approval in castration-resistant prostate cancer (CRPC), patients in GETUG-AFU 15 showed the relatively highest rates of febrile neutropenia. This suggests that docetaxel may be surprisingly more toxic in mCSPC. Additionally, docetaxel pharmacokinetics have proven to play a role in these variations of toxicity rates.
This presentation reviews the data examining the possibility that if docetaxel leads to greater toxicity in patients in a pre-castration state, then it may also lead to greater efficacy. An in vitro study, animal model, breast cancer study, and human trials in prostate cancer have explored this idea. It will also briefly discuss a current phase II trial introducing chemotherapy prior to ADT. Finally, It will review the current issues physicians should consider when initiating ADT.
About the International Prostate Cancer Update
The International Prostate Cancer Update (IPCU) is an annual, multi-day CME conference focused on prostate cancer treatment updates. The conference’s faculty consists of international experts, and the event caters to urologists, medical oncologists, radiation oncologists, and other healthcare professionals. Topics encompass prostate cancer management, from diagnosis to treating advanced and metastatic disease. Dr. Keane presented this lecture during the 29th IPCU in 2019. Please visit this page in order to learn more about future IPCU meetings.